Observational Study to Observe the Safety of NovoMix® 30 Treatment in Patients With Type 2 Diabetes
Launched by NOVO NORDISK A/S · Aug 5, 2008
Trial Information
Current as of June 04, 2025
Completed
Keywords
ClinConnect Summary
No description provided
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • Any patient with diabetes type 2 diabetes
- • Currently treated with basal human insulin therapy (basal only or in combination with oral glucose lowering drugs or other insulin
- • Selection of patients will be at the discretion of the treating physician after the decision to prescribe one of the study products to the patient
- Exclusion Criteria:
- • Known or suspected allergy to study product(s) or related products
- • Pregnancy, breast-feeding or intention of becoming pregnant within the next 6 months
About Novo Nordisk A/S
Novo Nordisk A/S is a global healthcare company headquartered in Denmark, specializing in the research, development, manufacturing, and marketing of innovative pharmaceuticals, particularly in the fields of diabetes care, obesity treatment, and hormone replacement therapies. With a strong commitment to improving patient outcomes, Novo Nordisk invests significantly in clinical trials to advance scientific knowledge and develop effective therapies. The company is dedicated to sustainability and ethical practices, striving to deliver high-quality healthcare solutions while addressing the evolving needs of patients worldwide. Through collaboration and innovation, Novo Nordisk aims to lead the way in transforming diabetes and other chronic diseases into manageable conditions.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Rud, , Norway
Farsta, , Sweden
Patients applied
Trial Officials
Global Clinical Registry (GCR, 1452)
Study Director
Novo Nordisk A/S
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials